{"id":"W4389233179","doi":"10.1182/blood-2023-174718","title":"Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Oncology; Venetoclax; Ibrutinib; Chemoimmunotherapy; Lymphoma; Gastroenterology; Chronic lymphocytic leukemia; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003863782,0.0001822612,0.0007854973,0.0003188526,0.00003220738,0.00002193741,0.0001151875,0.00006433067,0.00001303128],"category_scores_gemma":[0.00006102462,0.000124196,0.00001636398,0.0007183828,0.0001200031,0.00009811111,0.0000822189,0.00007376569,0.000009244486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00191407,"about_ca_system_score_gemma":0.001807731,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002257126,"about_ca_topic_score_gemma":0.0003676174,"domain_scores_codex":[0.9983728,0.0001930906,0.0003444859,0.0003601049,0.0004308263,0.0002987091],"domain_scores_gemma":[0.9991745,0.0002499645,0.0001127898,0.0002822958,0.00008686709,0.00009357934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5361667,0.3497571,0.08651675,0.0004715877,0.0008713252,0.002184089,0.01445998,0.00002388192,0.0002371626,0.00003963344,0.00004632684,0.009225444],"study_design_scores_gemma":[0.9662595,0.01099258,0.01738059,0.0001923935,0.0002772093,0.00001179325,0.001163616,0.002276865,0.001304934,0.0000108314,0.000007965984,0.0001217269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994315,0.00005596617,0.000001139349,0.00001900348,0.00001154625,0.005124488,0.00001415216,0.00001981289,0.0004389254],"genre_scores_gemma":[0.9991441,0.00004651258,0.0000895042,0.000009215479,0.000006236829,0.0003454675,0.00007517012,0.00002984085,0.0002539226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4300928,"threshold_uncertainty_score":0.5064564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02358003933382442,"score_gpt":0.3151918053041063,"score_spread":0.2916117659702819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}